Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT01490099
Surveillance Study of NovoRapid® for New Drug Re-examination
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1239
- Registration Number
- NCT01490112
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01489111
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT01489644
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2134
- Registration Number
- NCT01487421
Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01486914
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes
Phase 4
Terminated
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: human soluble insulin
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT01486966
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: biphasic human insulin 30
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 45
- Registration Number
- NCT01486888
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 598
- Registration Number
- NCT01486940
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Falun, Sweden
Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01486862
© Copyright 2025. All Rights Reserved by MedPath